Can you prepare a PowerPoint presentation on Metabolic Associated Fatty Liver Disease (MAFLD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

MAFLD PowerPoint Presentation Outline

I'll provide you with a comprehensive PowerPoint structure on Metabolic Associated Fatty Liver Disease (MAFLD), now officially termed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) as of 2024 1.

Slide 1: Title & Terminology Update

MAFLD/MASLD: The Most Common Chronic Liver Disease Worldwide

  • Key Point: MAFLD terminology (2020) has been superseded by MASLD (2024) 1
  • Affects 1 in 3 adults globally 2
  • Previously called Non-Alcoholic Fatty Liver Disease (NAFLD)

Slide 2: Definition & Diagnostic Criteria

What is MASLD?

MASLD is diagnosed when hepatic steatosis is present PLUS one or more cardiometabolic risk factors, WITHOUT harmful alcohol intake 1

Cardiometabolic Risk Factors Include:

  • Type 2 diabetes
  • Obesity (BMI ≥25 kg/m² in Asians, ≥30 kg/m² in others)
  • Hypertension
  • Dyslipidemia (elevated triglycerides or low HDL)
  • Insulin resistance

Critical Advantage: Diagnosis based on affirmative criteria, not exclusion 3

Slide 3: Disease Spectrum & Natural History

From Steatosis to Cirrhosis

Disease Progression:

  1. Simple hepatic steatosis (fat accumulation)
  2. MASH (Metabolic dysfunction-associated steatohepatitis) - inflammation + hepatocyte injury
  3. Fibrosis (stages F0-F4)
  4. Cirrhosis
  5. Hepatocellular carcinoma (HCC)

Progression Rates in Chinese Cohorts 4:

  • Fibrosis progression: 19.2%-38.4% over 3-6 years
  • HCC incidence: 0-2.7% over 6-11 years
  • All-cause mortality: 2.0%-12.0% over 4.6-10 years

Slide 4: Pathophysiology

Complex Multisystem Disease Mechanisms

Core Pathogenic Mechanisms 5, 6:

  • Lipotoxicity: Excessive hepatic lipid accumulation
  • Insulin resistance: Primary driver of metabolic dysfunction
  • Mitochondrial dysfunction: Impaired energy metabolism and oxidative stress
  • Inflammatory signaling: Activation of pro-inflammatory pathways
  • Gut-liver axis: Dysbiosis and altered metabolite production
  • Adipose-liver axis: Dysfunctional adipose tissue releasing inflammatory mediators

Slide 5: Who to Screen - Case-Finding Strategy

Target Populations for MASLD Screening 1

Mandatory screening in:

  • Type 2 diabetes patients (highest priority)
  • Obesity with additional metabolic risk factors
  • Abnormal liver enzymes (elevated ALT/AST)
  • Radiological signs of hepatic steatosis on imaging

Risk Factors for Rapid Progression 4:

  • Diabetes/abnormal glucose (strongest predictor)
  • Overweight/obesity
  • Hypertension
  • Advanced age

Slide 6: Diagnostic Approach - Detecting Steatosis

First Step: Confirming Hepatic Steatosis

Recommended First-Line Test 2:

  • Liver ultrasound - identifies fat accumulation in hepatocytes

Alternative Imaging:

  • MRI-PDFF (Proton Density Fat Fraction) - quantifies steatosis
  • Controlled Attenuation Parameter (CAP) via transient elastography

Note: Liver biopsy not required for routine diagnosis 1

Slide 7: Fibrosis Assessment - The Critical Step

Stepwise Non-Invasive Fibrosis Evaluation 1

Step 1: Blood-Based Score

  • FIB-4 index (age, AST, ALT, platelet count)
    • Low risk: <1.3
    • Indeterminate: 1.3-2.67
    • High risk: >2.67

Step 2: If FIB-4 Indeterminate or Elevated

  • Transient elastography (FibroScan) - measures liver stiffness
  • Alternative: Enhanced Liver Fibrosis (ELF) test

Goal: Identify advanced fibrosis (≥F3), which predicts liver-related outcomes 1

Slide 8: HCC Surveillance Recommendations

Who Needs Hepatocellular Carcinoma Monitoring?

Mandatory surveillance 1:

  • All MASLD-related cirrhosis patients (strong recommendation)

Consider surveillance 1:

  • Severe fibrosis (F3 stage) - individualized risk assessment

Do NOT routinely screen 1:

  • Non-cirrhotic MASLD with fibrosis <F3

Surveillance Method:

  • Ultrasound + AFP (alpha-fetoprotein) every 6 months
  • MRI for high-risk patients with poor ultrasound visualization 1

Slide 9: Treatment - Lifestyle Modifications (Foundation)

Non-Pharmacological Therapy is First-Line 1

Weight Loss Targets:

  • 7-10% body weight reduction improves steatosis and inflammation
  • Greater weight loss (>10%) may regress fibrosis

Dietary Changes:

  • Mediterranean diet pattern
  • Reduce refined carbohydrates and saturated fats
  • Limit fructose intake

Physical Activity:

  • 150-200 minutes/week moderate-intensity exercise
  • Resistance training beneficial

Alcohol:

  • Discourage consumption even at low levels

Slide 10: Treatment - Metabolic Comorbidity Management

Optimize Cardiometabolic Risk Factors 1

For Type 2 Diabetes or Obesity:

  • Incretin-based therapies (GLP-1 receptor agonists)
    • Semaglutide
    • Tirzepatide (GLP-1/GIP dual agonist)
  • These improve liver histology while treating diabetes/obesity

For Severe Obesity:

  • Bariatric surgery - effective option for MASLD patients 1

Manage:

  • Hypertension (target <130/80 mmHg)
  • Dyslipidemia (statins are safe in MASLD)

Slide 11: Treatment - MASH-Targeted Pharmacotherapy

First FDA-Approved MASH Treatment 1

Resmetirom (Thyroid Hormone Receptor-β Agonist):

  • Indication: Non-cirrhotic MASH with significant fibrosis (stage ≥F2)
  • Evidence: Demonstrated histological improvement in steatohepatitis and fibrosis
  • Safety profile: Acceptable tolerability
  • Limitation: Dependent on local approval and labeling

Important: No MASH-targeted pharmacotherapy currently recommended for cirrhotic stage 1

Slide 12: Cirrhosis Management

Special Considerations for MASLD Cirrhosis 1

Key Management Components:

  • Metabolic drug adaptations - adjust doses for hepatic impairment
  • Nutritional counseling - prevent sarcopenia and malnutrition
  • Portal hypertension surveillance - screen for varices
  • HCC surveillance - ultrasound + AFP every 6 months
  • Liver transplantation - for decompensated cirrhosis

Avoid: Hepatotoxic medications and nephrotoxic agents

Slide 13: Multidisciplinary Approach

MASLD Requires Coordinated Care 1

Essential Team Members:

  • Primary care physician (screening, risk factor management)
  • Hepatologist (advanced disease, fibrosis assessment)
  • Endocrinologist (diabetes/metabolic optimization)
  • Dietitian (nutritional counseling)
  • Cardiologist (CVD risk management)

Rationale: MASLD has bidirectional connections with cardiometabolic diseases - treating one improves the other 1

Slide 14: Monitoring Disease Progression

Non-Invasive Monitoring Strategy 1

For Treatment Response:

  • MRI-PDFF: >30% relative reduction associated with MASH resolution
  • ALT reduction: >17 U/L decrease correlates with histological improvement
  • Repeat FibroScan: Monitor fibrosis changes (use cautiously at individual level)

Timing: Reassess every 1-2 years in stable patients, more frequently if high-risk

Liver biopsy: Reserved for clinical trials or individual cases requiring definitive assessment 1

Slide 15: Extrahepatic Complications

MASLD is a Multisystem Disease 6, 3

Increased Risk of:

  • Cardiovascular disease (leading cause of death in MASLD patients)
  • Type 2 diabetes (bidirectional relationship)
  • Chronic kidney disease (MAFLD shows better diagnostic accuracy for CKD than NAFLD) 3
  • Extrahepatic malignancies

Clinical Implication: Screen for and aggressively manage cardiovascular risk factors

Slide 16: Key Pitfalls to Avoid

Common Clinical Errors:

  • Assuming normal ALT excludes significant disease (ALT can be normal in advanced fibrosis)
  • Failing to screen diabetic patients (highest risk population)
  • Using ultrasound alone for fibrosis assessment (cannot detect fibrosis)
  • Delaying referral until cirrhosis develops
  • Advising complete alcohol abstinence without context (discourage but not absolute contraindication in early disease)
  • Withholding statins due to liver disease concerns (statins are safe and beneficial)

Slide 17: Future Directions & Emerging Therapies

Under Investigation 5, 6:

  • Extracellular vesicle (EV)-based diagnostics and therapeutics
  • FGF21 analogs (fibroblast growth factor)
  • PPAR agonists (peroxisome proliferator-activated receptor)
  • Anti-fibrotic agents targeting specific pathways
  • Microbiome modulation strategies

Research Gaps: Long-term mortality benefit from histological improvements needs confirmation 1

Slide 18: Take-Home Messages

Critical Points for Clinical Practice:

  1. MASLD affects 1 in 3 adults - screen high-risk populations systematically
  2. Diagnosis requires steatosis + metabolic dysfunction - affirmative criteria, not exclusion
  3. Fibrosis stage determines prognosis - use FIB-4 then elastography stepwise approach
  4. Lifestyle modification is foundation - 7-10% weight loss target
  5. GLP-1 agonists are game-changers - treat diabetes/obesity while improving liver disease
  6. Resmetirom available for F2-F3 MASH - first approved MASH-targeted therapy
  7. Cirrhosis requires HCC surveillance - ultrasound + AFP every 6 months
  8. Multidisciplinary care is essential - address liver and cardiometabolic disease together

This presentation structure is based primarily on the 2024 EASL-EASD-EASO clinical practice guidelines 1, which represent the most authoritative and current recommendations for MASLD management, supplemented with recent research on pathogenesis and epidemiology 5, 6, 2, 3, 4.

References

4
Research

[Natural history and risk factors of metabolic associated fatty liver disease in Chinese cohorts].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2026

Related Questions

In a diabetic patient requiring insulin, how can I minimize peripheral hyperinsulinemia and hepatic steatosis when using subcutaneous insulin therapy?
How is fatty liver diagnosed?
Is hepatic steatosis always present in cirrhosis secondary to metabolic‑dysfunction‑associated fatty liver disease?
What is the recommended first-line management for metabolic-associated fatty liver disease (MAFLD)?
What are the diagnostic criteria for Metabolic Associated Fatty Liver Disease (MAFLD)?
Can Procardia XL (extended‑release nifedipine) be used for hypertension in a patient with end‑stage renal disease?
What is the recommended workup and initial management for a 52‑year‑old man presenting with frequent neck paresthesia, a metallic (copper) taste, excessive sweating, and a single generalized tonic‑clonic seizure with jerking, eye rolling, foaming, and a post‑ictal state?
How should a lupus flare be treated and what are the considerations for using azathioprine?
How common are degenerative changes of the pubic symphysis in military personnel?
What is the appropriate pramipexole dose for a patient with an estimated glomerular filtration rate of 27 mL/min?
What is the recommended treatment for cellulitis of the foot in a pediatric patient?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.